bitmap-araris-logo-rgb (002).jpg
Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem
12. November 2024 08:00 ET | Araris Biotech
First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
Alterity.png
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
06. November 2024 07:35 ET | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Figure 1*
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25. April 2024 10:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Une nouvelle publica
Une nouvelle publication de Vect-Horus dans Pharmaceutics démontre comment les vecteurs peuvent améliorer l’adressage de molécules thérapeutiques vers des organes et tumeurs
22. April 2024 09:56 ET | Vect-Horus
Marseille, France, 22Avril - VECT-HORUS, l'entreprise de biotechnologie qui conçoit et développe des molécules « vecteurs » qui facilitent l’adressage de molécules thérapeutiques ou d’agents...
Logo Vect-Horus.jpg
Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and Tumors
22. April 2024 09:56 ET | Vect-Horus
Marseille, France, April 22 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21. März 2024 02:00 ET | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
respirerx.jpg
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
20. März 2024 08:30 ET | RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and...
Logo.png
GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1
10. Oktober 2023 03:00 ET | GPCR Therapeutics
SEOUL, Korea and REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced today the expansion of its...
Logo.png
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
05. Oktober 2023 08:45 ET | GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...
tiziana-logo.png
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
06. September 2023 07:00 ET | Tiziana Life Sciences Ltd.
The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...